BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.38
+0.08 (0.86%)
At close: Aug 7, 2026, 4:00 PM EDT
9.42
+0.04 (0.43%)
After-hours: Aug 7, 2026, 7:51 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, BioCryst Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $20.82. The average 1-year stock price forecast is 121.96% higher than the current stock price, while the lowest is $12 (+27.93%) and the highest is $32 (+241.15%).
Price Target: $20.82 (+121.96%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $32 | Buy | Maintains | $32 | +241.15% | Aug 6, 2026 |
| Wedbush | Wedbush | Buy Maintains $20 | Buy | Maintains | $20 | +113.22% | Aug 6, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $14 → $13 | Buy | Reiterates | $14 → $13 | +38.59% | Aug 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 | Buy | Maintains | $30 | +219.83% | Aug 6, 2026 |
| Needham | Needham | Buy Maintains $16 | Buy | Maintains | $16 | +70.58% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
709.66M
from 874.84M
Decreased by -18.88%
Revenue Next Year
735.54M
from 709.66M
Increased by 3.65%
EPS This Year
0.79
from 0.63
Increased by 24.47%
EPS Next Year
0.99
from 0.79
Increased by 25.32%
EPS and Forward PE are based on non-GAAP adjusted numbers.